CONNECT WITH US
HealthTech

HealthTech

Commonly used drug kills leukemia cells early by acting mainly on RNA, not DNA

Medical Xpress logo

Published on

Add as a preferred source on Google
Commonly used drug kills leukemia cells early by acting mainly on RNA, not DNA

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

For more than two decades, azacitidine has been a major treatment for blood cancers such as high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The drug was thought to work through DNA, by stripping off the chemical tags that keep genes silenced and allowing those genes to switch back on.

Understanding how azacitidine works matters because the drug helps only a third to half of patients, and doctors have no reliable way to predict who will benefit.

In a recent study published in Molecular Cell, researchers at the University of Chicago and UT Health San Antonio report that during the first day of treatment, when the drug kills the most cancer cells, almost none of it happens in DNA, but instead mostly in RNA. There, it strips chemical tags from RNA and shuts down genes that cancer cells need to divide and repair their DNA. The research findings point to NSUN2, the enzyme that installs those tags, as a more precise drug target.

Scientists have long classified azacitidine as a DNA hypomethylating agent because a fraction of the drug ends up in DNA, but that DNA-centric model left major clinical puzzles unsolved. Changes in gene activity after treatment often did not match changes in DNA methylation , a process that adds or removes chemical tags from DNA molecules and changes their activity. Some patients benefited from the drug, even without measurable DNA demethylation.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.